Company Page - CORNERSTONE THERAPEUTICS INC

2000 Regency Parkway	Research Report	Earnings Snapshot - Last 08/06/17
Cary, NC 27518	Fact Sheet
Phone: 919-678-6611	Financial Statements
	Peer Comparison
	Annual Reports

Craig A. Collard, Chmn./Pres./CFO, David Price, CFO
Development of products designed to treat asthma and critical care diseases through regulation of the body's inflammatory response, as occurs within the body's immune system following a stimulus such as infection or trauma. Most advanced product is Zyflo®, a tablet formulation of zileuton, FDA approved in 1996, for prevention and chronic treatment of asthma. IPO at $7 May 26, 2004. Raised $42 million, selling 6 million shares, 25% of the outstanding. Lead Manager: SG Cowen Securities Corp. Formerly CRITICAL THERAPEUTICS INC until merger October 31, 2008.

Historical Charts Technical Analysis

No Historical Data available for CRTX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)

Common CRTX $9.62 $ 0 $9.551 $9.77 54,075 $3.1 $10.37 12,357

Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121

Common Stock $118,874

Split, Dividend and Symbol Change Information

Date Symbol Transaction Dividend Split New Symbol

01-DEC-08 CRTXD Symbol Changed to CRTX

07-NOV-08 CRTX Split 1 for 10

03-NOV-08 CRTX Symbol Changed to CRTXD

Date	Symbol	Transaction	Split	New Symbol
01-DEC-08	CRTXD	Symbol Changed to		CRTX
07-NOV-08	CRTX	Split	1 for 10
03-NOV-08	CRTX	Symbol Changed to		CRTXD

QUICK NAVIGATION			SITE SEARCH Enter Keyword:

Home Subscribe Browser Help Subscriber Services B-to-B Banks Brokerage Telco Site Map Legal Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex